The company will also be awarded a patent term adjustment of an additional 470 days, providing Eurand with coverage on Amrix until at least February 26, 2025.
Eurand’s patent will include claims covering Amrix (cyclobenzaprine hydrochloride), a product currently marketed in the US by Cephalon, under license from Eurand. Amrix is said to be the only approved once-daily formulation of the skeletal muscle relaxant, cyclobenzaprine hydrochloride, for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.
Gearoid Faherty, CEO of Eurand, said: “This newly issued patent will be particularly meaningful given Cephalon’s commitment to the product and its success thus far in the US marketplace.”